Abstract EMS-312 a dual toll-like receptor (TLR2/9) antagonist is the product of a structure activity testing campaign that involved 400+ synthesized analogs. This compound represents a first-in-class approach to suppressing the inflammatory network that fuels aggressive cancers. EMS-312 selectively blocks the intracellular TLR2/9-MyD88 signaling complex. As shown in Table 1, EMS-312 is orally available and crosses the blood-brain barrier. By targeting a shared innate-immune pathway, EMS312 can address multiple indications—from glioblastoma, triple negative breast cancer, and pancreatic cancer while also qualifying for orphan and fast-track designations. Comprehensive composition-of-matter patents have been issued and are active through 2039. EMS312 shows a clean safety and ADME package, with compelling early proof of tumor-cell and microglial suppression. EMS-312 sits at the locus of oncology where big pharma currently appears to have a pipeline gap, giving this drug lead candidate significant partnering and acquisition potential. Citation Format: Milan Makale, Wolfgang Wrasidlo. A novel toll-like receptor antagonist lead for glioblastoma and pancreatic and breast cancer abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5139.
Makale et al. (Fri,) studied this question.